Agoracom: Small Cap Investment - Mosaic ImmunoEngineering Inc. - Profit & Loss for MIG pursuant to Moore Discl Statement

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Back To Forum List View

l2007s

Rank: President [?]

Points: 18410 [?]

Votes: 123 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Profit & Loss for MIG pursuant to Moore Discl Statement

posted on Sep 09, 2014 06:42PM

6 yr total (2015-2020) for MIG

Tot Rev Forecast $200,000

Licensing Revenue 45,000

Litigation Revenue $155,000

Net to PDS $130,625

Royalties Paid

PTSC (50%) $65,313

Also pursuant to Moore Discl Statement

Pro Forma Profit & Loss Statement 2015-2020 for TPL

MMP Royalty Revenue 66 yr total 34,060

Non MMP Royalty Revenue 20,000

pgs 97-99

http://photos.imageevent.com/banos/tplbk/Disclosure%20Statement%20Filed%20by%20Requestor%20Charles%20H.%20Moore%208-28-14.pdf

3 Recommendations

Re: Profit & Loss for MIG pursuant to Moore Discl Statement

medtech7309

Sep 09, 2014 08:53PM

Reply New Message

Back To Forum List View

Please to post a reply